265 related articles for article (PubMed ID: 25599163)
41. T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes.
Devillier R; Bramanti S; Fürst S; Sarina B; El-Cheikh J; Crocchiolo R; Granata A; Chabannon C; Morabito L; Harbi S; Faucher C; Santoro A; Weiller PJ; Vey N; Carlo-Stella C; Castagna L; Blaise D
Bone Marrow Transplant; 2016 Feb; 51(2):194-8. PubMed ID: 26551778
[TBL] [Abstract][Full Text] [Related]
42. Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience.
Aguilera DG; Vaklavas C; Tsimberidou AM; Wen S; Medeiros LJ; Corey SJ
J Pediatr Hematol Oncol; 2009 Nov; 31(11):803-11. PubMed ID: 19801947
[TBL] [Abstract][Full Text] [Related]
43. Peripheral Blood CD34 Donor Chimerism has Greater Clinical Utility Than CD3 for Detecting Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Das TP; North D; Fleming SA; Tan JLC; Ivey A; Cummings NJ; Spencer A; Patil SS; Widjaja JML; Swain MI; Bourke C; O'Brien ME; Kliman DS; Curtis DJ
Transplant Cell Ther; 2023 Jul; 29(7):454.e1-454.e8. PubMed ID: 36966870
[TBL] [Abstract][Full Text] [Related]
44. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.
Schroeder T; Czibere A; Platzbecker U; Bug G; Uharek L; Luft T; Giagounidis A; Zohren F; Bruns I; Wolschke C; Rieger K; Fenk R; Germing U; Haas R; Kröger N; Kobbe G
Leukemia; 2013 Jun; 27(6):1229-35. PubMed ID: 23314834
[TBL] [Abstract][Full Text] [Related]
45. [The clinical analysis of allogeneic hematopoietic stem cell transplantation from human leukocyte antigen-identical siblings in 95 patients with myelodysplastic syndrome].
Zhao T; Huang X; Liu D; Wang J; Zhang X; Wang Y; Han W; Chen H; Chen Y; Wang F; Liu K; Xu L
Zhonghua Nei Ke Za Zhi; 2014 Feb; 53(2):89-93. PubMed ID: 24767157
[TBL] [Abstract][Full Text] [Related]
46. MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation.
Wermke M; Schmidt A; Middeke JM; Sockel K; von Bonin M; Schönefeldt C; Mair S; Plodeck V; Laniado M; Weiss G; Schetelig J; Ehninger G; Theurl I; Bornhäuser M; Platzbecker U
Clin Cancer Res; 2012 Dec; 18(23):6460-8. PubMed ID: 22991415
[TBL] [Abstract][Full Text] [Related]
47. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
48. Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation.
Alam N; Atenafu EG; Kuruvilla J; Uhm J; Lipton JH; Messner HA; Kim DH; Seftel M; Gupta V
Bone Marrow Transplant; 2015 Sep; 50(9):1180-6. PubMed ID: 26121109
[TBL] [Abstract][Full Text] [Related]
49. Outcome of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with central nervous system involvement.
Aoki J; Ishiyama K; Taniguchi S; Fukuda T; Ohashi K; Ogawa H; Kanamori H; Eto T; Iwato K; Sakamaki H; Morishima Y; Nagamura T; Atsuta Y; Takami A
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2029-33. PubMed ID: 25196856
[TBL] [Abstract][Full Text] [Related]
50. Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia.
Craddock C; Slade D; De Santo C; Wheat R; Ferguson P; Hodgkinson A; Brock K; Cavenagh J; Ingram W; Dennis M; Malladi R; Siddique S; Mussai F; Yap C
J Clin Oncol; 2019 Mar; 37(7):580-588. PubMed ID: 30653424
[TBL] [Abstract][Full Text] [Related]
51. CD34(+) lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT.
Rosenow F; Berkemeier A; Krug U; Müller-Tidow C; Gerss J; Silling G; Groth C; Wieacker P; Bogdanova N; Mesters R; Büchner T; Kienast J; Berdel WE; Stelljes M
Bone Marrow Transplant; 2013 Aug; 48(8):1070-6. PubMed ID: 23376821
[TBL] [Abstract][Full Text] [Related]
52. Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (allo-HSCT) by analyzing survival end points in defined groups of acute myeloid leukemia patients: a retrospective, multicenter Polish Adult Leukemia Group study.
Grosicki S; Holowiecki J; Kuliczkowski K; Skotnicki A; Hellmann A; Kyrcz-Krzemien S; Dmoszynska A; Sułek K; Kloczko J; Jedrzejczak WW; Warzocha K; Zdziarska B; Wierzbowska A; Pluta A; Komarnicki M; Giebel S
Am J Hematol; 2015 Oct; 90(10):904-9. PubMed ID: 26149802
[TBL] [Abstract][Full Text] [Related]
53. Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome.
Mo XD; Xu LP; Zhang XH; Liu DH; Wang Y; Chen H; Yan CH; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Bone Marrow Transplant; 2015 Jan; 50(1):127-33. PubMed ID: 25387095
[TBL] [Abstract][Full Text] [Related]
54. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).
de Witte T; Suciu S; Meert L; Halkes C; Selleslag D; Bron D; Amadori S; Willemze R; Muus P; Baron F
Ann Hematol; 2015 Dec; 94(12):1981-9. PubMed ID: 26410352
[TBL] [Abstract][Full Text] [Related]
55. Prognostic factors in allo-SCT of elderly patients with AML.
Krauter J; Wagner K; Stadler M; Dammann E; Zucknick M; Eder M; Buchholz S; Mischak-Weissinger E; Hertenstein B; Ganser A
Bone Marrow Transplant; 2011 Apr; 46(4):545-51. PubMed ID: 20548341
[TBL] [Abstract][Full Text] [Related]
56. Allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndrome: Experience of the Argentinean Group of Bone Marrow Transplantation (GATMO).
Basquiera AL; Rivas MM; Remaggi G; Klein G; Milovic V; Foncuberta MC; Saba S; Milone JH; Arbelbide J; Jaimovich G; Rolón JM; Kusminsky G; García JJ; Prates MV
Hematology; 2016 Apr; 21(3):162-9. PubMed ID: 26147089
[TBL] [Abstract][Full Text] [Related]
57. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
58. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
59. Prognostic Prediction Model for Second Allogeneic Stem-Cell Transplantation in Patients With Relapsed Acute Myeloid Leukemia: Single-Center Report.
Park SS; Kim HJ; Min KI; Min GJ; Jeon YW; Yoon JH; Yahng SA; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):e167-e182. PubMed ID: 29519618
[TBL] [Abstract][Full Text] [Related]
60. Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial.
Kuhlen M; Willasch AM; Dalle JH; Wachowiak J; Yaniv I; Ifversen M; Sedlacek P; Guengoer T; Lang P; Bader P; Sufliarska S; Balduzzi A; Strahm B; von Luettichau I; Hoell JI; Borkhardt A; Klingebiel T; Schrappe M; von Stackelberg A; Glogova E; Poetschger U; Meisel R; Peters C
Br J Haematol; 2018 Jan; 180(1):82-89. PubMed ID: 29193007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
